Share to: share facebook share twitter share wa share telegram print page

Tedatioxetine

Tedatioxetine
Clinical data
Other namesLu AA24530; Lu-AA-24530
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21NS
Molar mass283.43 g·mol−1
3D model (JSmol)
  • CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
  • InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 checkY
  • Key:CVASBKDYSQKLSO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]

Tedatioxetine is reported to act as a triple reuptake inhibitor (serotonin > norepinephrine > dopamine) and 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptor antagonist.[2][3][4][5]

As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]

On May 10, 2016, all work on tedatioxetine stopped.[8]

A Chinese patent shows that there has been interest in this compound outside of Lundbeck.[9]

See also

References

  1. ^ Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma.
  2. ^ US 2010144788, Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", published 10 June 2010, assigned to H Lundbeck AS 
  3. ^ Stahl SM (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
  4. ^ Stolerman IP (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
  5. ^ a b "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009.
  6. ^ "Pipeline of Lundbeck". Archived from the original on 28 September 2012. Retrieved 25 August 2013.
  7. ^ "Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.
  8. ^ "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.
  9. ^ WO 2015090160, Cao, Longji; Xin, Jianchuang & Yang, Xiangping, "Compound for preparing 4-(2-(4-methylphenylthio))phenylpiperidine, and preparation method and use thereof", published 2015-06-25, assigned to NHWA Pharma Corp. 


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Kembali kehalaman sebelumnya